Inactive Instrument

Press Releases Intercept Pharmaceuticals, Inc.

Equities

ICPT

US45845P1084

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC	Feb. 29	AQ
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023	Nov. 13	AQ
Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023	Nov. 10	AQ
Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.	Nov. 09	AQ
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.	Nov. 08	AQ
Intercept: Q3 Earnings Snapshot	Nov. 07	AQ
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTA, SPLK, ICPT, FNCB	23-10-24	PR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMTI, ICPT, FNCB	23-10-18	PR
INTERCEPT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intercept Pharmaceuticals, Inc. - ICPT	23-10-16	BU
INTERCEPT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intercept Pharmaceuticals, Inc. - ICPT	23-09-27	BU
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ICPT, PFSW, AVTA, CATC	23-09-26	PR
Shareholder Alert: Ademi LLP investigates whether Intercept Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Alfasigma	23-09-26	PR
ICPT Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Intercept Pharmaceuticals to Alfasigma	23-09-26	AQ
ICPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intercept Pharmaceuticals, Inc. Is Fair to Shareholders	23-09-26	BU
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases	23-09-26	AQ
Intercept Pharmaceuticals : Corporate Presentation – September 2023	23-09-08	PU
Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences	23-09-05	AQ
Intercept Pharmaceuticals : Corporate Presentation – August 2023	23-08-02	PU
Intercept: Q2 Earnings Snapshot	23-08-02	AQ
Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates	23-08-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Intercept Pharmaceuticals, Inc.

Equities

ICPT

US45845P1084

Press Releases

Filters